Valneva (VALN) Competitors $3.99 -0.36 (-8.28%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VALN vs. CALT, ANIP, SNDX, SPRY, RCKT, AVDL, BCYC, COLL, SEPN, and ZYMEShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Calliditas Therapeutics AB (publ) (CALT), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), Rocket Pharmaceuticals (RCKT), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), Septerna (SEPN), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Calliditas Therapeutics AB (publ) ANI Pharmaceuticals Syndax Pharmaceuticals ARS Pharmaceuticals Rocket Pharmaceuticals Avadel Pharmaceuticals Bicycle Therapeutics Collegium Pharmaceutical Septerna Zymeworks Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking. Which has more volatility and risk, CALT or VALN? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Does the MarketBeat Community believe in CALT or VALN? Valneva received 5 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 60.38% of users gave Valneva an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% ValnevaOutperform Votes3260.38% Underperform Votes2139.62% Do insiders & institutionals have more ownership in CALT or VALN? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, CALT or VALN? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Valneva$158.54M2.04-$109.78M-$0.13-30.69 Is CALT or VALN more profitable? Valneva has a net margin of -4.35% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Valneva's return on equity of -3.93% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Valneva -4.35%-3.93%-1.42% Do analysts recommend CALT or VALN? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, indicating a potential downside of 1.88%. Valneva has a consensus price target of $18.50, indicating a potential upside of 363.66%. Given Valneva's stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CALT or VALN? In the previous week, Valneva had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Valneva and 0 mentions for Calliditas Therapeutics AB (publ). Valneva's average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Valneva is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Valneva Neutral SummaryValneva beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$324.18M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-30.6946.7389.9717.18Price / Sales2.04415.011,116.21116.99Price / CashN/A182.1042.8937.86Price / Book2.003.894.784.78Net Income-$109.78M-$42.21M$120.23M$225.60M7 Day Performance1.53%-2.15%-1.92%-1.23%1 Month Performance-9.73%4.20%11.49%3.36%1 Year Performance-60.10%18.39%30.57%16.60% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.1517 of 5 stars$3.99-8.3%$18.50+363.7%-62.2%$324.18M$158.54M-30.69700News CoverageHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180ANIPANI Pharmaceuticals4.836 of 5 stars$56.36-0.4%$77.71+37.9%+1.9%$1.19B$555.46M-102.89642Insider TradeSNDXSyndax Pharmaceuticals3.952 of 5 stars$13.79-1.0%$37.64+172.9%-33.6%$1.18B$16M-3.80110News CoverageSPRYARS Pharmaceuticals3.1441 of 5 stars$11.89-0.1%$24.00+101.9%+121.8%$1.16B$30,000.00-23.3390Insider TradeNews CoverageRCKTRocket Pharmaceuticals4.8477 of 5 stars$11.76-2.2%$51.00+333.7%-58.6%$1.07BN/A-4.37240Analyst ForecastAVDLAvadel Pharmaceuticals2.6635 of 5 stars$10.93+5.2%$24.43+123.5%-24.0%$1.05B$138.16M-13.15154Positive NewsBCYCBicycle Therapeutics3.6062 of 5 stars$15.12+9.5%$36.00+138.1%-18.8%$1.04B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeCOLLCollegium Pharmaceutical3.8414 of 5 stars$30.72+2.1%$42.60+38.7%-0.4%$990.72M$599.25M13.24210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.69-3.1%$43.67+101.3%N/A$963.04MN/A0.00N/AZYMEZymeworks2.8055 of 5 stars$13.77+9.5%$18.83+36.8%+52.5%$948.48M$76.01M-9.25290Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies CALT Alternatives ANIP Alternatives SNDX Alternatives SPRY Alternatives RCKT Alternatives AVDL Alternatives BCYC Alternatives COLL Alternatives SEPN Alternatives ZYME Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VALN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
